Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Completed · Phase 2

Conditions studied: Ovarian Neoplasm

In brief

The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.

Key facts

Study ID

NCT00494442

Run by

AstraZeneca

People needed

58

Starts

2007-06-11

Expected to finish

2017-07-20

Last updated by the study team

2018-08-01

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Advanced ovarian cancer with positive BRCA1 or BRCA2 status
• Failed at least one prior chemotherapy
• In investigators opinion, no curative standard therapy exists
• Measurable disease

You may not qualify if…

• Brain metastases
• Less than 28 days since last treatment used to treat the disease
• Considered a poor medical risk due to a serious uncontrolled disorder

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — New York, New York, United States
• Research Site — Houston, Texas, United States
• Research Site — Melbourne, Australia
• Research Site — Melbourne, Parkville, Australia
• Research Site — Randwick, Australia
• Research Site — Cologne, Germany
• Research Site — Hospitalet deLlobregat, Spain
• Research Site — Lund, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.